Oncology Corporate Profile
1.0900 | |
0.0700 |
Idera Pharmaceuticals is a clinical stage biotechnology company developing a novel approach to the treatment of autoimmune diseases and certain genetically defined forms of B-cell lymphoma. Our most advanced clinical programs are based on nucleic acid therapeutics designed to inhibit overactivation of Toll-like receptors. Idera is conducting clinical development of TLR antagonists in autoimmune and inflammatory diseases, and preclinical development of their use in certain genetically defined forms of B-cell lymphoma.
Website: http://www.iderapharma.com/
Brand / Product | Class | Area of Study | Phase | Partnership |
---|---|---|---|---|
IMO-2125 (+ ipilimumab) | TLR9 agonist | Melanoma | I | |
IMO-2125 | TLR9 agonist | Various cancer types | Preclinical |